A Phase 1/2 interventional study of Dexmethylphenidate 5 Mg Oral Capsule, Extended Release and Dexmethylphenidate 6.25 mg Tablet in ADHD, sponsored by Cingulate Therapeutics. Completed at 1 site in United States. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2021-04-08.
Sponsored by Cingulate Therapeutics · Phase 1/2, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States — 98 open to participants now, 116 under way, 5 of them phase 3. Attention Deficit Disorder with Hyperactivity · United States.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, this one is the 431st largest by enrollment of the 706 interventional ones that give a count, is one of 32 that started in 2019, is one of 14 in phase 1/2, and was the 574th registered.
1,817 studies on the registry are indexed under Attention Deficit Disorder with Hyperactivity; 295 are open to participants now.
Browse Attention Deficit Disorder with Hyperactivity studies →98 of the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States are open now. Recruiting first, the newest first:
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–17
National Institute of Mental Health (NIMH) · Sites in United States
Ages 8–13
National Institute of Mental Health (NIMH) · Sites in United States
Ages 10–17 · Healthy volunteers
Otsuka Pharmaceutical Development & Commercialization, Inc. · Sites in United States
Ages 18–65
Alkermes, Inc. · Sites in United States
Ages 18–65
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 201 Attention Deficit Disorder with Hyperactivity studies recruiting now, 27 (13%) set no upper age limit and 169 (84%) stop at 75 or younger; 141 take children under 18; 55 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
807 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 62 · Phase 2 108 · Phase 3 135 · Phase 4 148
First in 1985; this study’s year is marked. 32 started in 2019.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 45 is below the median of 71 across 1,437 interventional studies indexed under Attention Deficit Disorder with Hyperactivity.
Median enrollment 70 across the 706 interventional studies, 115 across the 98 observational. Of the 644 that completed or were terminated, 302 (47%) have results posted.
This tab as a report to print or save as PDF → With an account.
262 of 807 have an industry lead sponsor. The 10 most frequent:
Cingulate Therapeutics is the lead sponsor of 6 studies on the registry; none are open to participants now.
Of its 5 completed or terminated interventional studies of FDA-regulated products, 3 (60%) have results posted.
Cingulate Therapeutics has 4 studies filed under Attention Deficit Disorder with Hyperactivity — fewer than ten, so there is no comparison to draw.
34 of the studies in Attention Deficit Disorder with Hyperactivity with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT07759154Phase 3Otsuka Pharmaceutical Development & Commercialization, Inc.A Study to Test the Effects of Centanafadine in Adults With Attention-deficit/Hyperactivity Disorder and Emotional Dysregulation | 2027-05-27 |
| NCT04278404Duke UniversityPharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs Administered to Children Per Standard of Care (POPS) | 2026-11 |
| NCT04946253University of PittsburghSKIP for PA Study: Team and Leadership Level Implementation Support for Collaborative Care | 2026-11 |
| NCT05683756University of PittsburghOptimizing Attention and Sleep Intervention Study | 2026-12 |
| NCT07594730New York State Psychiatric InstituteBrief Intervention Addressing Stigma Among Parents of Children With Mental Health Problems | 2026-12-01 |
Add all 34 to your calendar (.ics) → With an account.
Among the 807 studies in Attention Deficit Disorder with Hyperactivity with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The primary purpose of this study is to compare the bioavailability of CTx-1301 (dexmethylphenidate) to the registered listed drug, Focalin XR and to evaluate dose proportionality of CTx-1301. In addition, this study seeks to characterize the pharmacokinetics of dexmethylphenidate and evaluate the safety and tolerability of CTx-1301.
The study will comprise of a randomized, single-dose, four-sequence, four-period, in-clinic crossover study in approximately 36 adult ADHD subjects. All subjects considered eligible at Screening will proceed to tolerability test day, dosing 40 mg Focalin XR to evaluate safety and tolerability of the higher dose of d-MPH. If subject is able to safely tolerate the test dose, and meets all inclusion/exclusion criteria, they will be considered eligible for randomization into the study. All subjects will be randomized to receive four treatments throughout the course of the study; one CTx-1301 trimodal d-MPH tablet containing 6.25 mg d-MPH, one Focalin 5 mg XR capsule, one CTx-1301 50 mg tablet, and one 40 mg Focalin XR capsule. Administration of study drug will occur only on Assessment Days; no study drug will be administered during screening or unscheduled days (USVs).
The lowest and highest doses of CTx-1301 (dexmethylphenidate, 6.25 and 50 mg) were selected to bridge to the lowest and highest doses of Focalin XR (dexmethylphenidate, 5 and 40 mg) in this comparative BA study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Gender
a. Male or Female
Age
a. Aged between 18 and 55 years inclusive.
Weight and
Compliance
Indication
General Health
Smoking/Caffeine/Alcohol
ADHD Medication History
Exclusion Criteria:
Medical History
Medications
a. Subject has taken any medication that, in the opinion of an Investigator, has been shown to alter the PK of d-MPH.
b. Use of any prescription medication within 14 days prior to Day -3 (ADHD medications must be discontinued at least 96 hours prior to check-in at Day -4), and/or use of any OTC medications (such as antacids, vitamins, minerals, dietary/herbal preparations, and nutritional supplements) within 7 days prior to Day -3 unless jointly approved by an Investigator and Sponsor.
i. Subjects are permitted to take hormonal and hormone replacement therapy at acceptable levels if stable at least 30 days prior to Day -4, through the duration of the study, and for 30 days after the study ends.
ii. Acetaminophen (up to 2 grams per day) may be used during the study under the direction of the Investigator.
iii. On a case-by-case basis, an Investigator is permitted to allow the use of certain concomitant medications, for example, to treat an AE, as long as an Investigator determines that the medication will not affect the subject's safety or study integrity (eg, topical medications).
Alcohol/Substance Abuse
Smoking
a. Subject regularly smokes more than 10 cigarettes/day (or other nicotine-containing products) or Subject has recently discontinued smoking (within the last 3 months)
Allergy/Intolerance
a. Subject has a history of allergy to d-MPH, to any component of the dosage form, or any other allergy, which, in the opinion of an Investigator, contraindicates their participation.
Clinical Studies
Personnel
a. An employee of the sponsor, study site, or members of their immediate family.
Blood
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
BMI (body mass index)
Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.
What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis B tests
Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.
Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hepatitis C tests
Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.
After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECG (electrocardiogram)
A recording of the heart’s electrical activity, taken with stickers on the chest, arms and legs. It takes a few minutes and does not hurt.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Subjects in sequence ADBC will receive study treatments in the following order: Focalin XR 5 mg capsule, CTx-1301 50 mg tablet, CTx-1301 6.25 mg tablet, Focalin XR 40 mg capsule.
Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 6.25 mg Tablet · Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 50 mg Tablet
Subjects in sequence BACD will receive study treatments in the following order: CTx-1301 6.25 mg tablet, Focalin XR 5 mg capsule, Focalin XR 40 mg capsule, CTx-1301 50 mg tablet.
Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 6.25 mg Tablet · Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 50 mg Tablet
Subjects in sequence CBDA will receive study treatments in the following order: Focalin XR 40 mg capsule, CTx-1301 6.25 mg tablet, CTx-1301 50 mg tablet, Focalin XR 5 mg capsule.
Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 6.25 mg Tablet · Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 50 mg Tablet
Subjects in sequence DCAB will receive study treatments in the following order: CTx-1301 50 mg tablet, Focalin XR 40 mg capsule, Focalin XR 5 mg capsule, CTx-1301 6.25 mg tablet.
Drug: Dexmethylphenidate 5 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 6.25 mg Tablet · Drug: Dexmethylphenidate 40 Mg Oral Capsule, Extended Release · Drug: Dexmethylphenidate 50 mg Tablet
Reference listed drug (RLD) for comparative BA evaluation
Also known as: Focalin XR (dexmethylphenidate) 5 mg Capsule
Experimental drug for comparative BA evaluation
Also known as: CTx-1301 (dexmethylphenidate) 6.25 mg Tablet
Reference listed drug (RLD) for comparative BA evaluation
Also known as: Focalin XR (dexmethylphenidate) 40 mg capsule
Experimental drug for comparative BA evaluation
Also known as: CTx-1301 (dexmethylphenidate) 50 mg tablet
Cmax
d-MPH Plasma concentration
Time frame: Hours 0 to 28
AUC(0-infinity)
Area under the curve from time 0 extrapolated to infinite time
Time frame: Hours 0 to 28
AUC(Last)
AUC from time 0 to the last measurable concentration
Time frame: Hours 0 to 28
Partial AUCs
AUC from Hours 0-3, 3-6, 6-9, 9-12, and 12 to 16
Time frame: Hours 0 to 28
K
Rate at which a drug is removed from the system
Time frame: Hours 0 to 28
Half-life
Time (Hours) it takes for the concentration of the drug in plasma to be reduced by 50%
Time frame: Hours 0 to 28
Tmax
Time (Hours) after administration of a drug when the maximum plasma concentration is reached
Time frame: Hours 0 to 28
Tlag
Delay (hours) between the time of dosing and time of appearance of concentration in the sampling
Time frame: Hours 0 to 28
Incidence of Treatment-Emergent Adverse Events
TEAEs will be measured from Day 0 to Day 10 (End of Study)
Time frame: Day 0 to Day 10
Subjects were recruited at a single site from November 22, 2019 to March 06, 2020.
| Milestone | Sequence 1 (ADBC) | Sequence 2 (BACD) | Sequence 3 (CBDA) | Sequence 4 (DCAB) |
|---|---|---|---|---|
| Started | 11 | 10 | 12 | 12 |
| Completed | 10 | 10 | 10 | 9 |
| Not completed | 1 | 0 | 2 | 3 |
d-MPH Plasma concentration
| pg/mL | Treatment A | Treatment B | Treatment B/A | Treatment C | Treatment D | Treatment D/C |
|---|---|---|---|---|---|---|
| Cmax | 3138.41 (2893.862 to 3403.633) | 2874.52 (2646.813 to 3121.816) | 0.92 (0.843 to 0.995) | 23884.13 (22050.942 to 25869.722) | 24685.37 (22774.231 to 26756.894) | 1.03 (0.953 to 1.120) |
Area under the curve from time 0 extrapolated to infinite time
| ng/mL | Treatment A | Treatment B | Treatment B/A | Treatment C | Treatment D | Treatment D/C |
|---|---|---|---|---|---|---|
| AUC(0-infinity) | 24384.31 (22579.167 to 26333.776) | 27661.46 (25603.455 to 29884.885) | 1.13 (1.090 to 1.181) | 203127.64 (188123.507 to 219328.465) | 239317.53 (221590.471 to 258462.729) | 1.18 (1.133 to 1.225) |
AUC from time 0 to the last measurable concentration
| pg/mL | Treatment A | Treatment B | Treatment B/A | Treatment C | Treatment D | Treatment D/C |
|---|---|---|---|---|---|---|
| AUC(Last) | 22793.45 (20666.366 to 25139.474) | 25540.99 (23149.418 to 28179.632) | 1.12 (1.075 to 1.169) | 190456.27 (172736.598 to 209993.654) | 221949.48 (201261.408 to 244764.129) | 1.17 (1.118 to 1.214) |
AUC from Hours 0-3, 3-6, 6-9, 9-12, and 12 to 16
| hr*pg/mL | Treatment A | Treatment B | Treatment B/A | Treatment C | Treatment D | Treatment D/C |
|---|---|---|---|---|---|---|
| AUC0-3 | 4928.24 (4520.066 to 5373.276) | 3943.21 (3612.595 to 4304.075) | .80 (0.743 to 0.861) | 37963.37 (34854.010 to 41350.112) | 32744.35 (30044.791 to 35686.470) | .86 (0.803 to 0.927) |
| AUC3-6 | 6939.76 (6357.221 to 7575.675) | 6317.47 (5778.203 to 6907.071) | 0.91 (0.831 to 0.997) | 51204.34 (46939.593 to 55856.559) | 51368.60 (47085.223 to 56041.632) | 1.00 (0.918 to 1.096) |
| AUC6-9 | 5644.67 (5176.704 to 6154.948) | 5624.50 (5149.945 to 6142.780) | 1.00 (0.909 to 1.093) | 49159.01 (45116.976 to 53563.164) | 53313.02 (48889.077 to 58137.277) | 1.08 (0.991 to 1.187) |
| AUC9-12 | 2769.68 (2498.675 to 3070.079) | 3638.05 (3277.387 to 4038.399) | 1.31 (1.198 to 1.440) | 25193.87 (22743.535 to 27908.203) | 34316.26 (30955.023 to 38042.466) | 1.36 (1.245 to 1.490) |
| AUC12-16 | 1643.22 (1458.189 to 1851.741) | 3092.55 (2739.223 to 3491.455) | 1.88 (1.679 to 2.109) | 15739.33 (13978.890 to 17721.462) | 26183.15 (23231.791 to 29509.457) | 1.66 (1.488 to 1.860) |
Rate at which a drug is removed from the system
| (1/hr) | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| K | 0.18 ± 0.053 | 0.16 ± 0.040 | 0.17 ± 0.035 | 0.16 ± 0.034 |
Time (Hours) it takes for the concentration of the drug in plasma to be reduced by 50%
| hr*pg/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Half-life | 3.77 ± 1.066 | 4.32 ± 1.866 | 4.05 ± 0.977 | 4.21 ± 1.163 |
Time (Hours) after administration of a drug when the maximum plasma concentration is reached
| hr*pg/mL | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Tmax | 5.00 (1.0 to 7.0) | 5.00 (1.0 to 7.0) | 6.00 (1.0 to 8.0) | 5.00 (1.0 to 10.0) |
Delay (hours) between the time of dosing and time of appearance of concentration in the sampling
| hr | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Tlag | 0.00 (0.0 to 0.5) | 0.00 (0.0 to 0.5) | 0.00 (0.0 to 0.5) | 0.00 (0.0 to 0.5) |
TEAEs will be measured from Day 0 to Day 10 (End of Study)
| participants | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| Incidence of Treatment-Emergent Adverse Events | 7 | 4 | 22 | 14 |
Collected over Day -4 to Day 10. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Treatment A | 0/41 (0%) | 0/41 (0%) | 7/41 (17.1%) |
| Treatment B | 0/39 (0%) | 0/39 (0%) | 4/39 (10.3%) |
| Treatment C | 0/43 (0%) | 0/43 (0%) | 22/43 (51.2%) |
| Treatment D | 0/42 (0%) | 0/42 (0%) | 14/42 (33.3%) |
| Event | Treatment A | Treatment B | Treatment C | Treatment D |
|---|---|---|---|---|
| TachycardiaCardiac disorders | 0/41 | 0/39 | 4/43 | 3/42 |
| HeadacheNervous system disorders | 0/41 | 1/39 | 3/43 | 2/42 |
| NauseaGastrointestinal disorders | 1/41 | 1/39 | 1/43 | 2/42 |
| Decreased AppetiteMetabolism and nutrition disorders | 0/41 | 0/39 | 1/43 | 2/42 |
| DizzinessNervous system disorders | 0/41 | 0/39 | 0/43 | 2/42 |
| AnxietyPsychiatric disorders | 0/41 | 0/39 | 1/43 | 2/42 |
| InsomniaPsychiatric disorders | 0/41 | 0/39 | 0/43 | 2/42 |
| IrritabilityPsychiatric disorders | 0/41 | 0/39 | 0/43 | 2/42 |
| PalpitationsCardiac disorders | 1/41 | 0/39 | 2/43 | 0/42 |
| Euphoric moodPsychiatric disorders | 1/41 | 0/39 | 2/43 | 1/42 |
| Age, Categorical(Participants) | Sequence 1 (ADBC) | Sequence 2 (BACD) | Sequence 3 (CBDA) | Sequence 4 (DCAB) | Total |
|---|---|---|---|---|---|
| <=18 years | 0 | 0 | 0 | 0 | 0 |
| Between 18 and 65 years | 11 | 10 | 12 | 12 | 45 |
| >=65 years | 0 | 0 | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | Sequence 1 (ADBC) | Sequence 2 (BACD) | Sequence 3 (CBDA) | Sequence 4 (DCAB) | Total |
|---|---|---|---|---|---|
| Female | 0 | 2 | 1 | 2 | 5 |
| Male | 11 | 8 | 11 | 10 | 40 |
| Ethnicity (NIH/OMB)(Participants) | Sequence 1 (ADBC) | Sequence 2 (BACD) | Sequence 3 (CBDA) | Sequence 4 (DCAB) | Total |
|---|---|---|---|---|---|
| Hispanic or Latino | 0 | 0 | 2 | 3 | 5 |
| Not Hispanic or Latino | 11 | 10 | 10 | 9 | 40 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Sequence 1 (ADBC) | Sequence 2 (BACD) | Sequence 3 (CBDA) | Sequence 4 (DCAB) | Total |
|---|---|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 | 0 | 0 |
| Asian | 1 | 0 | 0 | 1 | 2 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 | 0 | 0 |
| Black or African American | 3 | 4 | 6 | 5 | 18 |
| White | 7 | 6 | 6 | 6 | 25 |
| More than one race | 0 | 0 | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 | 0 |
| Region of Enrollment(participants) | Sequence 1 (ADBC) | Sequence 2 (BACD) | Sequence 3 (CBDA) | Sequence 4 (DCAB) | Total |
|---|---|---|---|---|---|
| United States | 11 | 10 | 12 | 12 | 45 |
| History of ADHD(participants) | Sequence 1 (ADBC) | Sequence 2 (BACD) | Sequence 3 (CBDA) | Sequence 4 (DCAB) | Total |
|---|---|---|---|---|---|
| Number | 11 | 10 | 12 | 12 | 45 |
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: No
Ran from Dec 2019 to primary completion in Mar 2020, 3 months.
Results were first posted in Apr 2021, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Mar 2021. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Dexmethylphenidate
Attention Deficit Disorder with Hyperactivity →
Cingulate Therapeutics